Intermittent Low-Dose Ritlecitinib in Refractory Pediatric Alopecia Areata: A Case Report with Therapeutic Implications

June 2025 in “ Acta Dermato Venereologica ”

Yitao Hu, Congman Xie, Mengyao Hu, Yongjun Chen, Ting Yang

Ritlecitinib Alopecia Areata pediatric alopecia refractory Alopecia Areata

TLDR Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This case report discusses the use of intermittent low-dose Ritlecitinib in a pediatric patient with refractory Alopecia Areata (AA). The treatment showed promising results, suggesting potential therapeutic benefits for children with AA. However, the report emphasizes the need for large-scale prospective studies to further evaluate the efficacy and safety of Ritlecitinib in pediatric AA patients.

View this study on medicaljournalssweden.se →

Discuss this study in the Community →

Related Community Posts Join

4 / 4 results

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 6 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community Article of all potential future cures

in Treatment 24 upvotes 10 months ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community How do we only have two treatments to combat hair loss at this point in time?

in Chat 211 upvotes 2 years ago

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

community Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials

in Research/Science 270 upvotes 8 months ago

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Related Research

1 / 1 results

research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child

April 2019 in “International journal of research in dermatology”

A child with rough nails also had hair loss and allergies.